CDK4 and breast carcinoma: In the present paper, we review the relevant evidence concerning drug interactions and safety profiles of everolimus and the CDK4/6 inhibitors in use in clinical practice in Italy for the treatment of HR-positive metastatic breast cancer and discuss the toxicities associated with this novel approach to the treatment of breast cancer.